Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation

• Published in: Brain tumor pathology Vol. 31; no. 3; pp. 172 - 176
• Main Authors: Tanaka, Shingo, Nakada, Mitsutoshi, Nobusawa, Sumihito, Suzuki, Satoshi O., Sabit, Hemragul, Miyashita, Katsuyoshi, Hayashi, Yutaka
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.07.2014; Springer Nature B.V
• Subjects: Amino Acid Substitution - genetics; Antigens; Astrocytoma - genetics; Astrocytoma - pathology; Brain cancer; Brain Neoplasms - genetics; Brain Neoplasms - pathology; Cancer Research; Case Report; Child; Cytoplasm; Female; Glioblastoma - genetics; Glioblastoma - pathology; Glutamic Acid; Humans; Kinases; Labeling; Magnetic Resonance Imaging; Medicine; Medicine & Public Health; Mutation; Necrosis; Neoplasms, Second Primary - genetics; Neoplasms, Second Primary - pathology; Neurology; Neurosurgery; Oncology; Pathology; Proteins; Proto-Oncogene Proteins B-raf - genetics; Surgery; Time Factors; Valine; United States > US; Japan; Epithelioid glioblastoma; BRAF; Pleomorphic xanthoastrocytoma
• ISSN: 1433-7398; 1861-387X
• DOI: 10.1007/s10014-014-0192-2

Pleomorphic xanthoastrocytoma (PXA) is classified by the World Health Organization as a grade II astrocytic tumor with relatively favorable prognosis among gliomas. A valine-to-glutamic acid substitution at position 600 of the serine/threonine-protein kinase BRAF ( BRAF V600E) mutation, which is commonly found in PXA, has recently been detected in approximately 50 % of all epithelioid glioblastoma (GBM) cases. We herein report a case of epithelioid GBM developing at the site of a left temporal PXA 13 years after the treatment of the primary tumor. The BRAF V600E mutation was detected in both tumors. These findings suggest that epithelioid GBM may arise from a PXA with a BRAF V600E mutation.